Pharmaceutical Technology
NOVEMBER 27, 2024
In recent years, the evolution of biologic therapies for severe asthma has paralleled advancements in other chronic conditions such as rheumatoid arthritis and psoriasis, where biologics have also transformed treatment paradigms.
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 27, 2024
The hypertension drug rilmenidine has been shown to slow down aging in worms, an effect that in humans could hypothetically help us live longer and keep us healthier in our latter years. Previous research has shown rilmenidine mimics the effects of caloric restriction on a cellular level.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
NOVEMBER 27, 2024
Pharmaceutical professionals expect digital solutions to solve drug development headaches, with AI already proving disruptive.
Bio Pharma Dive
NOVEMBER 27, 2024
The biotechnology company, which sees itself as "pretty conservative," recently put out an ambitious long-term revenue forecast for its schizophrenia and depression medicine Caplyta.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
NOVEMBER 27, 2024
In an advancement for diabetes management, the US Food and Drug Administration (FDA) has granted clearance to Medtronic’s new InPen app, setting the stage for the launch of the company’s Smart MDI system integrated with the Simplera continuous glucose monitor (CGM).
Bio Pharma Dive
NOVEMBER 27, 2024
Kronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC disclosed negative Phase 2 results for its ALS drug candidate utreloxastat.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
NOVEMBER 27, 2024
A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 million in cash and another $325 million in equity investment.
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 27, 2024
Union government is emphasising that the biotechnology sector’s thrust should be towards twin technologies. One is digital tech and the other is green tech which will help it transition towards sustainable development and foster low-carbon economy growth.
Pharmaceutical Technology
NOVEMBER 27, 2024
The Norse Eight trial was part of the data requested by the FDA after the agency rejected the BLA for the company’s Lytenava last year.
Fierce Pharma
NOVEMBER 27, 2024
The competition among three TROP2 antibody-drug conjugates is ent | The competition among three TROP2 antibody-drug conjugates is entering a new stage as Kelun-Biotech’s Merck & Co.-partnered sacituzumab tirumotecan has become the second therapy in the class to win a marketing approval.
Pharmaceutical Technology
NOVEMBER 27, 2024
The EC has granted approval to Novartis' Kisqali (ribociclib) plus an aromatase inhibitor to treat early breast cancer patients.
XTalks
NOVEMBER 27, 2024
World AIDS Day 2024 serves as a reminder of the ongoing fight against the human immunodeficiency virus, or HIV and acquired immunodeficiency syndrome, or AIDS. Marked each year on December 1, this day highlights progress in addressing one of the most significant public health challenges. This year’s theme , “Take the Rights Path to End AIDS,” emphasizes the importance of human rights in eradicating the epidemic.
Pharmaceutical Technology
NOVEMBER 27, 2024
With expected sales for GLP1Rs in obesity estimated to surpass $126 billion by 2030, this drug category presents a lucrative market.
Fierce Pharma
NOVEMBER 27, 2024
Two months after Sanofi completed construction in France of its innovative Modulus vaccine and biologics plant—which can be reconfigured within days during a pandemic—the drugmaker said it has
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
NOVEMBER 27, 2024
Arrowhead has entered a worldwide licensing and partnership agreement with Sarepta Therapeutics for rare genetic disease treatments.
Fierce Pharma
NOVEMBER 27, 2024
Before Exelexis’ Cabometyx can pass muster with the FDA in its hopeful neuroendocrine tumors indication next April, it will have to first face the agency’s Oncologic Drugs Advisory Committee ( | The agency's Oncologic Drugs Advisory Committee is set to discuss the treatment and its phase 3 CABINET study in March ahead of the FDA's planned decision date of April 2025.
Pharmaceutical Technology
NOVEMBER 27, 2024
The EC has approved BeiGene’s PD-1 inhibitor Tevimbra in combination with chemotherapy to treat ESCC and G/GEJ adenocarcinoma.
pharmaphorum
NOVEMBER 27, 2024
Novartis' fast-growing breast cancer drug gets another growth driver as EU approves adjuvant use in patients with early-stage HR+, HER2- tumours.
Pharmaceutical Technology
NOVEMBER 27, 2024
The FDA has delayed its decision on Soleno Therapeutics investigational therapy for children with Prader-Willi syndrome.
Fierce Pharma
NOVEMBER 27, 2024
Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer antidepressant, reduced bouts of cataplexy and other narcolepsy symptoms in Axsome's ENCORE study.
Pharmaceutical Technology
NOVEMBER 27, 2024
Idorsia has extended its cash runway into 2025 via an exclusivity fee for global rights negotiations for Tryvio.
Fierce Pharma
NOVEMBER 27, 2024
On a routine basis in recent years, headlines about layoffs in the biopharma industry have surfaced as companies large and small have been cutting costs and restructuring. | A survey of life sciences CEOs found that 94% plan to grow their workforce over the next three years, with 37% envisioning that the head count of their company will grow by at least 6%.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Technology
NOVEMBER 27, 2024
Acadia Pharmaceuticals has secured an exclusive global licence from Saniona to develop and commercialise SAN711.
XTalks
NOVEMBER 27, 2024
In this episode, Ayesha spoke with Thomas Heineman, MD, PhD, Chief Medical Officer at Oncolytics Biotech , a company developing an oncolytic virus cancer therapeutic that is currently in clinical trials for indications including metastatic breast cancer and pancreatic cancer. Oncolytics is developing a first-in-class, nonpathogenic oncolytic virus administered intravenously that activates, recruits and trains immune cells to identify and destroy cancer cells.
pharmaphorum
NOVEMBER 27, 2024
Learn how AI can accelerate the Medical, Legal, and Regulatory (MLR) review process. Discover strategies for leveraging AI to streamline and optimise MLR review in the medical, legal, and regulatory fields.
XTalks
NOVEMBER 27, 2024
Syndax Pharmaceuticals’ Revuforj (revumenib) has won US Food and Drug Administration (FDA) approval for the treatment of relapsed or refractory (R/R) acute leukemia in patients aged one year and older who have a lysine methyltransferase 2A ( KMT2A, formerly MLL ) gene translocation. The approval marks the first menin inhibitor to receive FDA clearance, offering a novel therapeutic option for this challenging leukemia subtype.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Commerce
NOVEMBER 27, 2024
In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Chase Feiger, MD, co-founder, Ostro, discusses the value of AI technology when it comes to tackling digital commercialization challenges.
XTalks
NOVEMBER 27, 2024
Sanofi has announced a €40 million ($42.46 million) investment to enhance its biomanufacturing capabilities at the Lyon Gerland site in France. The initiative aims to bolster the production of Thymoglobulin (antithymocyte globulin [rabbit]), a treatment for kidney transplant rejection, and to localize the manufacturing of type 1 diabetes therapy Tzield (teplizumab).
pharmaphorum
NOVEMBER 27, 2024
The 8th Gene Therapy Development Summit organized by Hanson Wade is a premier event showcasing the latest advancements in gene therapy. Learn more about this highly anticipated event here.
CTTI (Clinical Trials Transformation Initiative)
NOVEMBER 27, 2024
In November 2024, Lindsay Kehoe, senior project manager at CTTI, presented at the Digital Biomarkers Summit held at ETH Zurich. The event gathered experts from academia, healthcare, and industry to discuss the transformative potential of wearable technologies in healthcare. Among the many topics covered, a key focus was the translation of digital innovations, such as wearable devices for sweat and breath, into clinical implementation to revolutionize healthcare.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
246 
Let's personalize your content